Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Summary

DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 77+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Wet Age-Related Macular Degeneration (Wet-AMD): Understanding

Wet Age-Related Macular Degeneration (Wet-AMD): Overview

Wet age-related macular degeneration (AMD), also called exudative or neovascular AMD, is a form of AMD that primarily affects the macula, the central part of the retina responsible for detailed central vision. It is characterized by choroidal neovascularization (CNV), in which abnormal new blood vessels grow from the choroid through breaks in Bruch membrane and beneath or through the retinal pigment epithelium. These vessels can leak fluid and blood, causing retinal damage and central vision loss. Wet AMD is an important cause of central visual impairment and blindness among older individuals.

AMD is a multifactorial disease associated with several risk factors. Important risk factors include older age, smoking, family history, hypertension, cardiovascular disease, elevated total serum cholesterol, micronutrient deficiency, and exposure to visible light. Genetic predisposition also contributes to AMD, with multiple genetic loci and gene variants associated with disease development. Inflammation and activation of the complement pathway, including genetic variations involving complement factor H, are also implicated in the development of AMD.

Wet AMD is differentiated from early or dry AMD by the presence of CNV. New blood vessels from the choroid penetrate through Bruch membrane and proliferate between Bruch membrane and the RPE or in the subretinal space. Vascular endothelial growth factor (VEGF), particularly VEGF-165, contributes to CNV development. The new vessels can cause leakage of fluid, proteins, and lipids, hemorrhage, and growth of fibrous tissue. Fibrovascular scar formation can result in death of the neurosensory retina and vision loss.

Diagnosis of wet AMD relies on clinical examination and ocular imaging techniques. Patients may present with visual distortion or blurring of central vision, metamorphopsia, micropsia, or scotoma. Fundus examination may identify retinal hemorrhage, lipid, subretinal fluid, RPE detachment, or CNV-related changes. Optical coherence tomography (OCT) provides detailed images of the retina and can identify subretinal and intraretinal fluid, while fundus fluorescein angiography (FFA) helps identify and classify CNV. OCT angiography (OCTA) and indocyanine green angiography may also assist in detecting and characterizing neovascularization.

The mainstay of treatment for wet AMD is intravitreal anti-VEGF therapy, which prevents visual loss and may improve vision in some patients. Agents described include ranibizumab, aflibercept, bevacizumab, brolucizumab, and faricimab. Anti-VEGF agents reduce abnormal blood vessel growth and fluid leakage. Treatment may follow fixed-dose, pro re nata (PRN), or treat-and-extend regimens, with regular monitoring to assess disease activity and treatment response. Laser photocoagulation and photodynamic therapy (PDT) are additional treatment modalities but have largely been supplanted by anti-VEGF therapy.

"Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape is provided which includes the disease overview and Wet Age-Related Macular Degeneration (Wet-AMD) treatment guidelines. The assessment part of the report embraces, in depth Wet Age-Related Macular Degeneration (Wet-AMD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wet Age-Related Macular Degeneration (Wet-AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Wet Age-Related Macular Degeneration (Wet-AMD) R&D. The therapies under development are focused on novel approaches to treat/improve Wet Age-Related Macular Degeneration (Wet-AMD).

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs Chapters

This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs

• 4D-150: 4D Molecular Therapeutics/Otsuka Pharmaceutical

4D-150 is an investigational intravitreal gene therapy which comprises 4DMT’s proprietary, customized and evolved R100 AAV vector and a dual-transgene payload encoding aflibercept and a VEGF-C inhibitory RNAi. Following intravitreal administration, 4D-150 is designed to enable retinal expression of these transgenes, with aflibercept inhibiting VEGF-A, VEGF-B, and placental growth factor (PlGF), while the inhibitory RNAi suppresses VEGF-C. Thus, 4D-150 is designed to inhibit four angiogenic factors involved in wet AMD through its dual-transgene approach, with the goal of providing sustained anti-angiogenic activity following a single low-dose intravitreal administration. 4D-150 is a potential backbone therapy designed to provide multi-year, and potentially lifelong, sustained delivery of anti-VEGF biologics within the retina following a single intravitreal injection. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• AIV007: AiViva BioPharma, Inc.

AIV007 is an investigational therapy which is a broad-spectrum tyrosine kinase inhibitor, with lenvatinib as its active pharmaceutical ingredient, targeting vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), fibroblast growth factor receptors (FGFR-1, -2, -3, and -4), and platelet-derived growth factor receptors (PDGFR-? and -?). AiViva has formulated AIV007 using its proprietary JEL™ thermoresponsive gel technology for periocular administration, where it forms a durable posterior juxtascleral depot designed for prolonged drug release. Through inhibition of these multiple kinase pathways, AIV007 is designed to target the convergence of angiogenesis, fibrosis, and inflammation associated with retinal vascular diseases. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• BETA-TT8: Filamon LTD

BETA-TT8 is a small-molecule investigational drug developed by Filamon Limited for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD) and other inflammatory conditions of the eye. These BETA drugs are Type 4 kinase inhibitors of MEK1/ERK1 and that transcription factors including AP-1, FosB, ?FosB, cJun, and NF-?B are impacted, in turn affecting multiple genes involved in inflammation, angiogenesis, and immune-cell activity. BETA-TT8 is being developed in both oral and topical eyedropper formulations, with the eyedropper formulation designed to cross the cornea and reach the back of the eye at high drug levels. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• GO-2301: General Oncology

GO-2301 is a novel investigational drug candidate which induces terminal proliferation arrest and that a single molecule may irreversibly inhibit cell proliferation. GO-2301 is administered at nanogram concentrations and binding deep within the DNA helix, where it cannot be easily removed. When a cell attempts to proliferate, GO-2301 permanently traps the cell in M phase without causing the collateral cellular damage typically associated with alkylating agents. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

Further product details are provided in the report……..

Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment

This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Wet Age-Related Macular Degeneration (Wet-AMD)

There are approx. 75+ key companies which are developing the therapies Wet Age-Related Macular Degeneration (Wet-AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage, i.e. Phase III include, 4D Molecular Therapeutics and others.

• Phases

DelveInsight’s report covers around 77+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Wet Age-Related Macular Degeneration (Wet-AMD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet-AMD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet-AMD) drugs.

Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights

• Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Wet Age-Related Macular Degeneration (Wet-AMD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Wet Age-Related Macular Degeneration (Wet-AMD) drugs?
• How many Wet Age-Related Macular Degeneration (Wet-AMD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet-AMD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet-AMD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Elisigen Inc.
• Abbvie
• 4D Molecular Therapeutics
• AiViva BioPharma, Inc.
• Ashvattha Therapeutics
• Filamon LTD
• Innovent Biologics
• Ollin Biosciences
• Fujian Haixi Pharmaceuticals Co., Ltd.
• Frontera Therapeutics, Inc.
• Sylentis, S.A.
• General Oncology
• Adverum Biotechnologies
• Exegenesis Bio
• DotBio
• Otsuka Pharmaceutical
• REGENXBIO
• SCAI Therapeutics

Key Products

• NG101
• Surabgene Lomparvovec (ABBV-RGX-314)
• 4D-150
• AIV007
• Migaldendranib
• BETA-TT8
• IBI 324/OLN324
• HX9428
• FT-003
• SYL1801
• GO-2301
• Ixoberogene soroparvovec
• EXG102 031
• EXG202
• DB 013
• SCAI-005